We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Milestone Payment Amounts Sample Clauses

Milestone Payment AmountsThe Licensee will make a payment to CASE within thirty (30) days of each occurrence of the achievement of a Milestone as follows: MILESTONE MILESTONE PAYMENT AMOUNT […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…])
Milestone Payment AmountsThe Licensee will make a payment to CWRU within thirty (30) days of each occurrence of the achievement of a Milestone as follows: MILESTONE MILESTONE PAYMENT AMOUNT <INITIATE/COMPLETE> Phase I Clinical Trial $ <FEE> and <NUMBER> shares of Common Stock <INITIATE/COMPLETE> Phase II Clinical Trial $<FEE> and <NUMBER> shares of Common Stock <INITIATE/COMPLETE> Phase III Clinical Trial $<FEE> and <NUMBER> shares of Common Stock BLA Approval $<FEE> and <NUMBER> shares of Common Stock Product Launch $<FEE> and <NUMBER> shares of Common Stock This Section shall be construed as requiring separate Milestone payments for each and every Licensed Product that is subject to a Clinical Trial, BLA Approval and/or Product Launch and shall not be construed as limiting the number of times each Milestone can be achieved and for which payment is required. For example, $<FEE> and <NUMBER> shares of Common Stock shall be paid to CWRU for each Phase I Clinical Trial that is initiated.
Milestone Payment AmountsThe Licensee will make a payment to CWRU within thirty (30) days of the occurrence of the achievement of a Milestone in spinal cord injury or peripheral nerve injury as follows: MILESTONE MILESTONE PAYMENT AMOUNT First Dosing in a Phase I Clinical Trial [DOLLAR AMOUNT REDACTED ] First Dosing in a Phase II Clinical Trial [DOLLAR AMOUNT REDACTED] First Dosing in a Phase III Clinical Trial [DOLLAR AMOUNT REDACTED] FDA Approval and First Commercial Sale in USA [DOLLAR AMOUNT REDACTED] Regulatory Approval and First Commercial Sale outside the USA [DOLLAR AMOUNT REDACTED ] For the first and second Licensed Product that achieves a milestones set forth above in an Indication which is not spinal cord injury or peripheral nerve injury, the Licensee will make a payment to CWRU within thirty (30) days of the occurrence of the achievement of a Milestone at a rate which is [PERCENTAGE REDACTED] of the Milestone Payment Amount(s) listed above.
Milestone Payment AmountsThe Licensee will make a payment to CASE within thirty (30) days of each occurrence of the achievement of a Milestone as follows: MILESTONE MILESTONE PAYMENT AMOUNT [*]. [*] Dollars (U.S. [*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. [*]) [*] [*] Dollars (U.S. [*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) For purposes of this Section 5.5, a Combination Therapeutic will be deemed a second or third Combination Therapeutic if the therapeutic compound(s) comprising the additional formulation(s) (other than methoxyamine or a methoxyamine derivative) included in such Combination Therapeutic are not included in the Combination Therapeutic(s) that were the subject of an NDA or application for Disposition, as applicable, previously approved by the applicable regulatory body (i.e., are not included in the Combination Therapeutic(s) that triggered the preceding Milestone(s)).”
Milestone Payment Amounts. Subject to Parent’s Right of Setoff pursuant to Article VII, upon a Subsequent Payment Date, Parent shall, within five (5) Business Days following its receipt of the Milestone Payment Allocation Notification, pay (i) to each Equityholder who has complied with the procedures set forth in this Section 2.9 each such Equityholder’s portion of the Milestone Payment Amount payable upon achievement of the applicable Milestone and as set forth opposite such Equityholder’s name on the original Closing Date Allocation Schedule or the Future Payment Allocation Schedule delivered by the Equityholders’ Representative pursuant to Section 8.1(h), and (ii) to Stifel the Stifel Payment Amounts set forth on such Closing Date Allocation Schedule or Future Payment Allocation Schedule, in each case in immediately available funds by check or by wire transfer to such bank account or accounts as may be specified on such Closing Date Allocation Schedule or Future Payment Allocation Schedule. Notwithstanding anything in this Agreement to the contrary, in the event that any of the Second Subsequent Payment Date, Third Subsequent Payment Date or Fourth Subsequent Payment Date occurs and prior to such time, any earlier Milestone has not been achieved and thus its corresponding Subsequent Payment Date has not occurred and/or Milestone Payment Amount has not been paid (“Unpaid Milestones”), any such Unpaid Milestone shall be deemed to be achieved upon the achievement of such later Milestone and the applicable Milestone Payment Amounts shall all become payable upon the later Subsequent Payment Date; provided, however, that in the event that a New Drug Application has been submitted to the FDA prior to the initiation of the pivotal efficacy study contemplated by the First Milestone, then the First Milestone shall only become payable upon the earlier of achievement of the First Milestone or the achievement of the Third Milestone.
Milestone Payment AmountsThe Sublicensee will make a one-time payment on a Licensed Product by Licensed Product basis to NeoIndicate within thirty (30) days of each occurrence of the achievement of a Milestone as follows: (a) Diagnostic Licensed Product Milestone Payments: DIAGNOSTIC LICENSED PRODUCT(S) MILESTONE MILESTONE PAYMENT AMOUNT eIND or IND Diagnostic approval $ 75,000 First dose of Diagnostic in Phase I anywhere in world $ 75,000 First dose of Diagnostic in Phase II anywhere in world $ 150,000 First dose of Diagnostic in Phase III anywhere in world $ 300,000 US FDA Regulatory Approval Diagnostic $ 1,000,000 Outside of US Regulatory Approval Diagnostic $ 500,000 Upon first reaching cumulative aggregate gross sales of $25M Diagnostic $ 750,000 Upon first reaching cumulative aggregate gross sales of $100M Diagnostic $ 3,000,000 Upon first reaching cumulative aggregate gross sales of $250M Diagnostic $ 7,500,000 Upon first reaching cumulative aggregate gross sales of $500M Diagnostic $ 15,000,000 Upon first reaching cumulative aggregate gross sales of $1 Billion Diagnostic $ 30,000,000 Upon first reaching cumulative aggregate gross sales of $2 Billion Diagnostic $ 60,000,000 (b) Therapeutic Licensed Product Milestone Payments: THERAPEUTIC LICENSED PRODUCT(S) MILESTONE MILESTONE PAYMENT AMOUNT eIND or IND approval of therapeutic $ 100,000 First dosing Therapeutic of patients in Phase I anywhere in world $ 100,000 First dosing Therapeutic of patients in Phase II anywhere in world $ 200,000 First dosing Therapeutic of patients in Phase III anywhere in world $ 500,000 US FDA Approval Therapeutic $ 2,000,000 Outside of US Regulatory Approval Therapeutic $ 1,000,000 Upon first reaching cumulative aggregate gross sales of $25M Therapeutic $ 1,000,000 Upon first reaching cumulative aggregate gross sales of $100M Therapeutic $ 5,000,000 Upon first reaching cumulative aggregate gross sales of $250M Therapeutic $ 10,000,000 Upon first reaching cumulative aggregate gross sales of $500M Therapeutic $ 20,000,000 Upon first reaching cumulative aggregate gross sales of $1 Billion Therapeutic $ 40,000,000 Upon first reaching cumulative aggregate gross sales of $2 Billion Therapeutic $ 80,000,000 This Section shall be construed as requiring separate Milestone payments for each and every Licensed Product that is subject to a Clinical Trial, Regulatory Approval, and/or Product Launch and shall not be construed as limiting the number of times each Milestone can be achieved and for which payment ...

Related to Milestone Payment Amounts

  • Milestone Payment The first time Net Sales in the Territory in a Royalty Period exceed US$[***] ([***] dollars) US$[***] ([***] dollars)

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Milestone Payments (a) In partial consideration of the license rights granted by Marina Bio under this Agreement, MirnaRx shall pay to Marina Bio a milestone payment upon the first achievement by MirnaRx (independently of work done by or in collaboration with a Sublicensee) of the applicable milestone event set forth in the table below, such payments to be in the listed amounts for the applicable Milestone Event: (i) For each Licensed Product: [***] [***] (ii) For each Additional Indication for the Licensed Product, up to total of [***] Additional Indications: (1) [***] [***] (b) For clarity, each of the above milestone payments shall be paid only once for a particular Licensed Product, regardless if any such Milestone Event is achieved more than once, except that [***]. Further, if a particular Licensed Product achieves a particular Milestone Event under subclause (i) of the above table without having achieved a previous Milestone Event in such subclause (i), then such previous Milestone Event shall be deemed also achieved, and the Milestone Payment associated with such Milestone Event shall then be paid with the achievement of the subsequent Milestone Event. For illustrative purposes only, if the [***] Milestone Event as set forth in (i)(3) in the table above is not achieved for a Licensed Product but the [***] Milestone Event as set forth in (i)(4) above is achieved for such Licensed Product, then the Milestone Payment for achievement of the Milestone Event in clause (i)(3) [***] will be paid when the Milestone Payment for (i)(4) is paid. The total amount of milestone payments payable for a particular Licensed Product under the above shall not, in any event, exceed $6,000,000 under subclause (i) of the above table and $10,000,000 in total. For additional clarity, if MirnaRx (or its Affiliate) enters into a sublicense Agreement under which the applicable Sublicensee is granted sublicense rights to Commercialize a Licensed Product, then achievement of any of the above Milestone Events by such Sublicensee, or by MirnaRx or its Affiliate working in collaboration with such Sublicensee under the sublicense agreement, shall not create a Milestone Payment obligation, but instead MirnaRx shall have the obligation to share Sublicense Revenues received under such sublicense agreement as provided in Section 5.6 below. (c) Notwithstanding Sections 5.3(a) and 5.3(b) and the milestone table above, (i) no Milestone Payment for achievement of [***] of the milestone table above, and (ii) no [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Milestone Payments for [***] of the milestone table above, shall be payable with respect to any Licensed Product containing or incorporating miR-34. For clarity, Sections 5.3(a) and 5.3(b) and the milestone table above shall apply in full to all Licensed Products other than any Licensed Product containing or incorporating miR-34, unless the Parties mutually agree otherwise in writing. 1.7. The Parties acknowledge and agree that as of the Amendment Effective Date, the Milestone Payment for the achievement of the Milestone Event [***] of the milestone table above has been paid in full by MirnaRx [***]. 1.8. Section 5.4 shall be amended and restated in its entirety with the following:

  • Development Milestone Payments Pfizer shall make the payments set forth below within [**] days (or [**] days after [**] following the first occurrence of each event described below for a Licensed Product Covered by a Valid Claim that achieves such milestone (each event a “Development Milestone” and each payment a “Development Milestone Payment”). Development Milestone Development Milestone Payment [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]. The Development Milestone Payment in clause (2) of this Section 3.3 may become payable as set forth in Section 4.6. Whether or not the Development Milestone in clause (2) of this Section 3.3 is achieved, the Development Milestone Payment in clause (2) shall, pursuant to Section 4.6, in all cases become payable prior to the time the Development Milestone Payment in clause (3) of this Section 3.3 becomes payable. With respect to the Development Milestone in clause (3) of this Section 3.3, in the case of a [**] that is determined to have become [**], such Development Milestone, if achieved based on such [**], shall be achieved upon [**]; provided, however, if either [**], such Development Milestone shall be deemed to have been met on the date of such determination. With respect to the Development Milestone in clause (8) of this Section 3.3, such Development Milestone will be paid in [**], provided that if such Licensed Product [**]. (For the avoidance of doubt, all payment [**] that became payable prior to such [**] shall continue to be payable and there shall be [**] of the [**] Development Milestone Payment will be deemed to have been achieved and payable on [**], and will be paid by Pfizer within [**] days thereafter, until the earlier of [**]. For example, [**] of such Development Milestone, such Development Milestone Payment would be paid [**] of the Development Milestone [**]. For the avoidance of doubt: (a) except for (i) the Development Milestone Payment set forth in clause (6) of this Section 3.3 [**], (ii) the Development Milestone Payment set forth in clause (8) of this Section 3.3 [**] and (iii) the Development Milestone Payment set forth in clause (9) of this Section 3.3 [**], each Development Milestone Payment shall be payable only once upon achievement of the applicable Development Milestone and only on the first occurrence of the corresponding Development Milestone regardless of the number of Licensed Products and (b) satisfaction of a Development Milestone by an Affiliate or by a sublicensee or assignee of, or Third Party retained by, Pfizer or its Affiliates shall be deemed to have been satisfied by Pfizer for the purposes of this Section 3.3.

  • Milestone Fees Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent & Technology License Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) of the Patent & Technology License Agreement are achieved.

  • Milestone Event Milestone Payment [***] [***]

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Payment Amounts The aggregate Payments to be made in a fiscal year shall not exceed an amount equal to the corresponding Appropriated Amount (for example, for the Payments due on December 1, 2026 and on June 1, 2027, the aggregate maximum amount of such Payments would be determined by the Appropriated Amount determined for certification by December 1, 2025). Furthermore, the amount of each such Payment shall not exceed the Annual Percentage of Incremental Property Tax Revenues (excluding allocations of “back-fill” or “make-up” payments from the State of Iowa for property tax credits or roll-back) actually received by the City from the Marshall County Treasurer attributable to the taxable incremental valuation of the Property in the six (6) months immediately preceding such Payment due date.

  • Sales Milestones On a Co-Co Product-by-Co-Co Product basis, Celgene shall make the following sales milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the sales milestone events (“Sales Milestone Events”) set forth below with respect to sales of such Co-Co Product in the ROW Territory. [***] [***] [***] [***]

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and: (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless: (1) it will suffer significant uncompensated economic or operational harm from the delay, (2) attainment of the same milestone has previously been delayed, or (3) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.